MedTrace Logo

Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

NCT04448977 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-02-14

No results posted yet for this study

Summary

The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS). Cognitive fatigue is the kind of fatigue that occurs after intense mental concentration as after a session of problem solving.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Ocrevus

Participants with MS will be divided into two treatment groups: those who will begin to take Ocrevus (the "early Ocrevus" group (EO), and those who plan to be begin treatment with Glatimer acetate SC (Copaxone) (EC). Both groups will be matched to the EO group for age, gender and education. The HC group will be free of neurological disease or injury and will be matched to the EO group for age, gender, and education.

Sponsors & Collaborators

  • Hackensack Meridian Health

    collaborator OTHER

  • Kessler Foundation

    lead OTHER

Principal Investigators

  • John DeLuca, PhD · Kessler Foundation

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-06
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04448977 on ClinicalTrials.gov